Scarica l'app Stockscreener
1.30
7.44%
0.09
Dopo l'orario di chiusura:
1.28
-0.02
-1.54%
Precedente Chiudi:
$1.21
Aprire:
$1.2
Volume 24 ore:
2.77M
Relative Volume:
2.66
Capitalizzazione di mercato:
$10.97M
Reddito:
-
Utile/perdita netta:
$-7.51M
Rapporto P/E:
-0.9848
EPS:
-1.32
Flusso di cassa netto:
$-8.02M
1 W Prestazione:
+56.57%
1M Prestazione:
+40.85%
6M Prestazione:
+55.39%
1 anno Prestazione:
+15.04%
Intervallo 1D:
$1.16
$1.3621
Intervallo di 1 settimana:
$0.8292
$1.78
Portata 52W:
$0.58
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Nome
Hoth Therapeutics Inc
Settore
Industria
Telefono
(646)756-2997
Indirizzo
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Confronta HOTH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.30 | 10.97M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-10-15 | Iniziato | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Borsa (HOTH) Ultime notizie
Hoth Therapeutics advances with HT-001 oncology skin care treatment - Investing.com
First-Ever Treatment for EGFR Cancer Therapy Skin Toxicities: Experts Review Game-Changing Clinical Data - Stock Titan
Hoth Therapeutics, Inc. (NASDAQ:HOTH) Sees Large Increase in Short Interest - Defense World
Hoth Therapeutics (NASDAQ:HOTH) Stock Rating Upgraded by Wall Street Zen - Defense World
Hoth Therapeutics (NASDAQ:HOTH) Shares Up 0.7% – What’s Next? - Defense World
Hoth Therapeutics Faces Nasdaq Compliance Challenge - TipRanks
Hoth Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
HOTH THERAPEUTICS Earnings Results: $HOTH Reports Quarterly Earnings - Nasdaq
Hoth Therapeutics reports promising HT-KIT preclinical results By Investing.com - Investing.com Canada
Hoth Therapeutics, Inc. SEC 10-Q Report - TradingView
Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers - PR Newswire
Hoth Therapeutics reports promising HT-KIT preclinical results - Investing.com Australia
Hoth Therapeutics (HOTH) Expected to Announce Earnings on Tuesday - Defense World
Geode Capital Management LLC Purchases 13,038 Shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) - Defense World
Hoth Therapeutics confirms patent application fee payment By Investing.com - Investing.com Nigeria
Hoth Therapeutics confirms patent application fee payment - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Quarterly Snapshot: Quick and Current Ratios for Hoth Therapeutics Inc (HOTH) - DWinneX
Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Hoth secures Japan patent for RNA cancer therapy targeting KIT gene - Investing.com Canada
Hoth secures Japan patent for RNA cancer therapy targeting KIT gene By Investing.com - Investing.com South Africa
Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT GeneExpands Global IP in Precision Oncology Platform - PR Newswire
Hoth Therapeutics (HOTH) Reports Promising Phase 2a Results for Pruritus Treatment | HOTH Stock News - GuruFocus
Hoth Therapeutics reports progress in pruritus treatment trial By Investing.com - Investing.com South Africa
Hoth Therapeutics Announces Positive Initial Data In Phase 2A Clinical Trial - marketscreener.com
Hoth Therapeutics Reports Positive Phase 2a Trial Results - TipRanks
Hoth Therapeutics reports progress in pruritus treatment trial - Investing.com
Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial - Longview News-Journal
Hoth Therapeutics reports Alzheimer’s drug candidate success By Investing.com - Investing.com Nigeria
Hoth Therapeutics (HOTH) Reports Promising Data for Alzheimer's Candidate HT-ALZ - GuruFocus
Hoth Flat on Hookup with Washington Univ. - Baystreet.ca
Hoth Therapeutics reports Alzheimer’s drug candidate success - Investing.com India
Hoth Therapeutics Plans To Advance HT-ALZ Into Clinical Development - MarketScreener
Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ - Longview News-Journal
Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours - PR Newswire
Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World
Hoth Therapeutics receives USPTO filing receipt for HT-001 patent application - TipRanks
Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage - PR Newswire
Hoth Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Hoth Therapeutics Inc. (HOTH) reports earnings - Quartz
Hoth Therapeutics, Inc. SEC 10-K Report - TradingView
Hoth Therapeutics enhances patent claims, begins toxicity study By Investing.com - Investing.com South Africa
Hoth Therapeutics enhances patent claims, begins toxicity study - Investing.com
Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation - Marketscreener.com
Major Progress: Hoth's Cancer-Fighting Drug Secures Patent Protection and Launches Critical Safety Study - Stock Titan
Hoth Therapeutics Inc Azioni (HOTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):